GEM 21S Equimatrix Heli Products Mucograft References Download Center Video Education Center Lecture Materials
Professionals Patients Contact Us About Us
LOGIN SITE MAP

Privacy Policy

OSTEOHEALTH is the sole owner of the information collected on this Web site. We will not sell, share, or rent this information to others in ways different from what is disclosed in this statement. When you visit the OSTEOHEALTH Web site, you should be confident that we do our best to respect your privacy. We collect personally identifiable information only to answer your questions and concerns, provide you information you may have requested, and to learn what improvements we can make to our site and our products.

 

Mailing Lists
In some places on our site, you can select whether or not you want to receive future e-mails from us to learn about our products, or promotions, or general information about health. By selecting that you would like to receive such information, your email address and identifying information (name, address) will be kept in our internal database and used for that purpose only; it will not be shared with any third party, except one providing information on our behalf. If at any time you wish to be taken off an OSTEOHEALTH mailing list, please submit a message request to delete your name from our mailing lists by using our Contact Us page.

 

Personally Identifiable Information
We do not require you to disclose any personally identifiable information for general access to our site. Any personally identifiable information you submit is used only to help us satisfy your requests and for internal marketing purposes. Web site visitors may decide to send OSTEOHEALTH personally identifiable information, for example, in a message asking a question about an OSTEOHEALTH product or containing comments about the OSTEOHEALTH Web site. OSTEOHEALTH will use this information only to respond to the matter identified in the e-mail or as specified above.  Please note, however, that if you submit personally identifiable information about an adverse event or injury associated with use of one of our products, we may be required to submit that information to FDA or other regulatory agencies.

 

Non–Personally Identifiable Information
The OSTEOHEALTH Web site may collect non–personally identifiable information, such as type of browser, operating system, domain name, or IP address. An IP address is a number that is automatically assigned to your computer whenever you are surfing the Web. Web servers automatically identify your computer by its IP address. When you visit pages on the OSTEOHEALTH Web site, our servers log your IP address. We do not link IP addresses to any personally identifiable information. This means that your session will be logged, but you remain anonymous to us. Non–personally identifiable information is used only for internal marketing purposes and is then discarded. If you have any questions or comments about the OSTEOHEALTH Privacy Policy, please submit a message using our Contact Us page.

 

OSTEOHEALTH reserves the right to change our Privacy Policy from time to time. A revised Privacy Policy will apply to information collected after the date it is changed.

SEARCH:
Osteohealth Company   |   Contact Us   |   © 2014 Luitpold Pharmaceuticals, Inc. Company   |   Privacy Policy   |   Terms of Use
DAIICHI SANKYO NAMES NEW PRESIDENT OF US SUBSIDIARY LUITPOLD PHARMACEUTICALS, INC.

June 29, 2016 – Effective today, Ken Keller has been newly appointed as President and CEO of Luitpold Pharmaceuticals, in addition to his current position as President, Daiichi Sankyo Administrative and Commercial, Daiichi Sankyo, Inc.

With more than 25 years of experience in the pharmaceutical industry in commercial leadership and joint venture leadership, Mr. Keller will now oversee both the Daiichi Sankyo, Inc. Commercial organization and Luitpold Pharmaceuticals, Inc.

Mr. Keller joined Daiichi Sankyo, Inc. in 2014 and has also served on the Luitpold Board of Directors since 2015. He has successfully led the Daiichi Sankyo, Inc. US commercial organization as it begins its transformation to a specialty focused company.

“While Luitpold and Daiichi Sankyo US businesses serve different customers and markets, they each bring to the table important strengths and focus that are essential to the continued success and growth of the Daiichi Sankyo Group,” said Ken Keller. “I look forward to working with the Luitpold team and driving even further success in the future.”

Luitpold Pharmaceuticals, Inc. is a Daiichi Sankyo Group Company headquartered in Shirley, NY, and manufactures more than 80 pharmaceutical products.